Spero Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new investor Pfizer Inc. for private placement of 2,362,348 common shares $16.93 per share for gross proceeds of $39,994,551.64 on June 30, 2021. The company has raised funding as part of the Pfizer Breakthrough Growth Initiative. The company received funding from 1 investor pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -0.68% | -6.37% | 0.00% |
May. 15 | Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M | MT |
Mar. 13 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 79.76M | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.